KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Non-Current Assets over the past 16 years, most recently at $273.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 847.0% year-over-year to $273.4 million; the TTM value through Dec 2025 reached $361.8 million, up 179.28%, while the annual FY2025 figure was $273.4 million, 847.0% up from the prior year.
  • Non-Current Assets for Q4 2025 was $273.4 million at Rigel Pharmaceuticals, up from $27.6 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $273.4 million in Q4 2025 and troughed at $5.2 million in Q3 2022.
  • A 5-year average of $33.4 million and a median of $18.8 million in 2021 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: crashed 66.47% in 2022 and later surged 847.0% in 2025.
  • Year by year, Non-Current Assets stood at $12.9 million in 2021, then skyrocketed by 42.88% to $18.4 million in 2022, then dropped by 2.27% to $18.0 million in 2023, then skyrocketed by 60.77% to $28.9 million in 2024, then surged by 847.0% to $273.4 million in 2025.
  • Business Quant data shows Non-Current Assets for RIGL at $273.4 million in Q4 2025, $27.6 million in Q3 2025, and $31.3 million in Q2 2025.